LDN 8mg Weight Loss: A Woman’s Guide

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published August 4, 2025 • Updated May 3, 2026

If you found this article because someone told you LDN 8mg is the hidden answer for weight loss, I want you to slow down. Low-dose naltrexone is interesting. It may have a role in selected pain, immune, and inflammatory conditions. But interesting is not the same as proven, and off-label is not the same as harmless.

I see too many women arrive at Gaya Wellness after months of supplements, peptides, compounded medications, and “metabolism hacks” that were sold with more confidence than data. LDN belongs in that conversation because it is often described online as if it quietly fixes inflammation, cravings, autoimmune flares, insulin resistance, and stubborn weight. That is not how I practice medicine.

My position is direct: LDN 8mg may be reasonable for a carefully selected patient when the goal is not weight loss alone. It should not be sold to women as a primary obesity treatment when stronger metabolic options exist and when the evidence for LDN alone is still limited.

What LDN 8mg Actually Means

Naltrexone is an opioid receptor antagonist. At standard doses, it is used for alcohol use disorder and opioid use disorder. At lower compounded doses, often around 1.5mg to 4.5mg and sometimes higher, clinicians use it off-label under the label “low-dose naltrexone,” or LDN. An 8mg dose is much lower than a standard 50mg tablet, but it is higher than many classic LDN protocols.

That distinction matters. When a woman says she is taking LDN 8mg for weight loss, I want to know whether she is taking compounded naltrexone alone, a split tablet, or something being described as “like Contrave.” Those are not interchangeable. Contrave’s FDA label describes a fixed-dose extended-release tablet containing naltrexone 8mg with bupropion 90mg. The approved medication is a combination product, not LDN alone.

That does not mean every woman should take Contrave. It means we should be precise. Naltrexone plus bupropion has obesity trial data. Low-dose naltrexone alone has far less direct weight-loss evidence. If a clinician blurs that line, ask better questions before you start.

Why Women Are Hearing About LDN for Weight Loss

The pitch usually sounds logical. Inflammation can worsen metabolic health. Chronic pain can reduce activity. Poor sleep and autoimmune symptoms can raise stress physiology. If LDN helps some patients with pain or inflammatory symptoms, then maybe weight improves indirectly. That is plausible in individual cases, but plausible is not proof.

There are women whose weight changes because pain improves enough to move, sleep improves enough to recover, or inflammatory symptoms calm enough to support consistent eating. I do not dismiss those stories. I do, however, separate a helpful symptom tool from a weight-loss medication. A medication can improve one barrier without being a reliable fat-loss treatment.

This distinction protects women from another round of self-blame. If LDN helps pain but the scale barely moves, that does not mean you failed. It may mean the dominant driver was insulin resistance, menopause, medication effect, low muscle mass, sleep apnea, thyroid disease, alcohol, or an appetite pathway that LDN was never designed to treat.

At Gaya, weight is evaluated through the wider lens of stubborn weight gain, medical weight loss, hormones, body composition, and cardiometabolic risk. I am not interested in making a trendy medication carry a job it has not proven it can do.

What the Evidence Can and Cannot Say

The strongest obesity data involving naltrexone are for the combination of naltrexone and bupropion, not LDN alone. The NIH Endotext obesity pharmacotherapy review summarizes randomized trial results for approved anti-obesity medications and places bupropion-naltrexone in a moderate-effect category compared with newer incretin therapies. That is useful data, but it cannot be imported wholesale into LDN 8mg monotherapy.

The COR-BMOD trial tested naltrexone sustained release plus bupropion sustained release with intensive behavior modification for 56 weeks. That is a very different intervention from taking compounded LDN at night and hoping inflammation will melt abdominal fat. Different drug combination. Different dosing. Different trial design. Different claim.

The LDN literature is more focused on chronic pain, fibromyalgia, inflammatory and autoimmune symptom hypotheses, and emerging mechanisms. A 2025 PubMed-indexed scoping review described LDN as a developing treatment area for several conditions, but that is not the same as a high-quality obesity evidence base. If someone tells you “LDN works for weight loss because inflammation,” they are skipping several scientific steps.

My clinical translation is simple: LDN may be part of an individualized plan for a woman with pain, immune symptoms, or medication constraints. It should not delay evidence-based obesity care when the medical problem is significant weight gain, prediabetes, fatty liver risk, hypertension, sleep apnea, or rapid abdominal weight change.

I also want women to understand what “no strong evidence” means. It does not mean every anecdote is false. It means the claim has not cleared the standard I need before I call a treatment reliable for a population. Medicine has room for cautious off-label use, but it also has a duty to name uncertainty plainly.

The Safety Questions I Ask First

Naltrexone blocks opioid receptors. That is not a minor footnote. If you take opioid pain medication, use medication treatment for opioid dependence, recently had surgery requiring opioids, or may need opioid pain control, naltrexone can create serious problems. It can precipitate withdrawal in someone physically dependent on opioids and can make opioid pain medicine ineffective.

I also care about liver history, alcohol use, pregnancy and breastfeeding status, mood symptoms, headaches, sleep disruption, nausea, vivid dreams, and medication interactions. Women often assume low dose means low consequence. Sometimes that is true. Sometimes it is not. A lower dose can still be the wrong drug for the wrong patient.

Compounding quality matters too. Many LDN prescriptions are compounded because commercial tablets do not come in typical LDN doses. That means the prescriber, pharmacy, dose accuracy, fillers, titration schedule, and follow-up plan all matter. If you are given LDN without a medication review, opioid screen, liver-risk discussion, pregnancy context, and a defined reason for use, the plan is too casual.

I am especially cautious when women are also being treated for perimenopause symptoms, menopause symptoms, anxiety, insomnia, chronic pain, autoimmune disease, or post-surgical pain. Those are not reasons to panic. They are reasons to practice medicine instead of guessing.

When I Would Not Use LDN as the Main Weight Plan

If a woman has obesity with metabolic risk, prediabetes, significant food noise, binge-restrict cycling, fatty liver markers, hypertension, sleep apnea, or repeated failure of lifestyle-only plans, I do not want her spending another six months on an underpowered strategy. That is not skepticism for the sake of being difficult. It is respect for time.

Modern obesity care has better tools than it did ten years ago. GLP-1 and dual-incretin medications are not magic, and they are not appropriate for every woman. They can cause side effects, require monitoring, and need a nutrition and strength plan. But they have stronger clinical evidence for weight loss than LDN alone. That is why our weight loss injections discussions include medication selection, muscle protection, dose tolerance, labs, and long-term strategy.

For women in midlife, the medication decision also has to include hormones. Weight gain after 40 may be tied to poor sleep from hot flashes, lower estrogen, lower muscle mass, insulin resistance, thyroid changes, stress, alcohol, and medication side effects. If you only chase inflammation, you can miss the real driver. If you only chase the scale, you can miss the hormone story.

This is why I may coordinate Weight Loss Concierge with Hormonal Agency, hormone replacement therapy evaluation, or longevity medicine when appropriate. The right plan is not “LDN or GLP-1.” The right plan is the one that matches your physiology, risk, and goals.

A Better Way to Decide

Before using LDN 8mg for weight loss, I would ask five questions. First, what is the diagnosis we are treating? “Weight loss” is not specific enough. Are we treating obesity, cravings, pain, autoimmune symptoms, inflammation, insulin resistance, alcohol cravings, or medication limitations? Second, what would success look like after 12 weeks? Less pain, fewer flares, lower cravings, better sleep, weight loss, or better function?

Third, what safer or better-proven options have been considered? For one woman, the answer may be protein targets and strength training. For another, it may be semaglutide, tirzepatide, metformin, Contrave, menopause care, sleep apnea treatment, thyroid management, or a medication change. Fourth, what would make us stop? If there is no stop rule, there is no real treatment plan.

Fifth, are we protecting muscle? I do not care how elegant the medication theory sounds if the patient is losing muscle, under-eating protein, skipping resistance training, or using appetite suppression without supervision. Weight loss that leaves a woman weaker is not metabolic success.

Gaya’s approach to Ozempic and menopause weight loss, semaglutide treatment, and broader physician-led weight care is built around this point. The medication is one lever. It is not the whole plan.

Frequently Asked Questions

LDN 8mg is not nonsense. It is also not a shortcut around metabolic medicine. If it is being used for the right reason, with the right safety screening, in the right patient, I can have that conversation. If it is being sold as the missing secret for women’s weight loss, I am going to push back.

The most respectful thing I can do for a woman who has struggled with weight is refuse weak answers. You deserve a plan that looks at insulin, appetite, muscle, hormones, sleep, pain, medications, inflammation, and risk. You deserve evidence where evidence exists and honesty where it does not.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.